Ocular Therapeutix to Present Phase 3 Data, Highlight TKI Program at Key Retina Conferences

Event summary

  • Ocular Therapeutix will present data on its investigational AXPAXLI (OTX-TKI) at the ARVO and Retina World Congress conferences in May 2026.
  • Chief Development Officer Peter Kaiser and other executives will present at multiple scientific and investor conferences throughout May 2026.
  • The company will host fireside chats at the Bank of America Health Care Conference and the Stifel 2026 Virtual Ophthalmology Forum.
  • AXPAXLI is in Phase 3 clinical trials for wet AMD and diabetic retinal disease, leveraging the ELUTYX hydrogel technology.

The big picture

Ocular Therapeutix's conference participation underscores the company's focus on advancing its lead asset, AXPAXLI, through late-stage clinical development. The presentations provide a key opportunity to influence investor sentiment and shape perceptions of the drug's potential to compete in the crowded anti-VEGF market. Success hinges on demonstrating a differentiated efficacy and safety profile compared to existing treatments, which have a combined market value exceeding $15 billion annually.

What we're watching

Clinical Efficacy
The presentation of Phase 3 SOL-1 trial results for OTX-TKI will be critical in assessing the drug's potential to disrupt the anti-VEGF market, currently dominated by larger players.
Commercialization
The company's ability to effectively communicate the durability and sustained disease control benefits of OTX-TKI, as highlighted in the symposiums, will influence physician adoption and market penetration.
Pipeline Progression
The ongoing evaluation of next steps for the OTX-TIC program, a travoprost intracameral hydrogel, will reveal the company’s commitment to expanding its pipeline beyond its current focus.